Scarica l'app Stockscreener
21.34
0.09%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$21.32
Aprire:
$21.46
Volume 24 ore:
1.97M
Relative Volume:
1.00
Capitalizzazione di mercato:
$3.60B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
118.56
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-9.58%
1M Prestazione:
-17.89%
6M Prestazione:
+28.48%
1 anno Prestazione:
+38.75%
Intervallo 1D:
$20.87
$21.48
Intervallo di 1 settimana:
$20.02
$21.86
Portata 52W:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.34 | 3.60B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Why ACADIA Pharmaceuticals Inc. stock could be next big winner2025 Dividend Review & Entry Point Confirmation Signals - newser.com
News impact scoring models applied to ACADIA Pharmaceuticals Inc.Price Action & Reliable Volume Spike Trade Alerts - newser.com
JP Morgan Updates ACADIA Pharmaceuticals (ACAD) Analyst Rating | - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Will ACADIA Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWeekly Investment Report & Verified Swing Trading Watchlist - newser.com
Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Insider Selling & Real-Time Stock Movement Alerts - newser.com
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps - MSN
What analysts say about ACADIA Pharmaceuticals Inc stockMomentum Stock Picks & Budget Friendly Growth - earlytimes.in
What drives ACADIA Pharmaceuticals Inc stock priceAnalyst Downgrades & Market Crushing Stock Picks - Early Times
What machine learning models say about ACADIA Pharmaceuticals Inc.Index Update & Long-Term Growth Plans - newser.com
Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AIInsider Selling & Stepwise Trade Execution Plans - newser.com
Using flow based indicators on ACADIA Pharmaceuticals Inc.2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Acadia drops development of carbetocin in PWS - The Pharma Letter
Acadia to stop development of rare disease therapy after trial failure - ET Pharma
ACADIA Pharmaceuticals Hits Day Low of $20.03 Amid Price Pressure - Markets Mojo
Acadia Pharmaceuticals stock price target maintained by BMO after trial miss - Investing.com Canada
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - sharewise.com
Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says - MarketScreener
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $35 - 富途牛牛
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating - MarketScreener
Acadia, Harmony record late-stage rare disease failures - pharmaphorum
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - BioSpace
Acadia Pharmaceuticals stock price target lowered to $35 at TD Cowen - Investing.com
Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com
Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study By Investing.com - Investing.com UK
Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily
Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma
Acadia Pharmaceuticals: Reeling After PWS FailureDowngrading To Hold (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint By Investing.com - Investing.com Canada
Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges - MSN
BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure - Investing.com Canada
Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq
ACAD: Latest Developments and Market Insights - GuruFocus
Acadia Pharmaceuticals (ACAD) Faces Setback After Phase 3 Trial Results - GuruFocus
ACADIA Pharmaceuticals (ACAD): Needham Lowers Price Target, Maintains Buy Rating | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down Following Analyst Downgrade - MarketBeat
Acadia to scrap Prader-Willi drug after study setback - BioPharma Dive
Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint - Investing.com
Needham & Company LLC Has Lowered Expectations for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating By Investing.com - Investing.com UK
Acadia, with a failed phase III, drops Prader-Willi candidate - BioWorld MedTech
Acadia’s phase 3 trial for Prader-Willi syndrome drug fails to meet goals - Investing.com Australia
Traders Buy Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals (ACAD) Experiences Significant Drop in St - GuruFocus
Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target - TipRanks
Leerink on Acadia (ACAD): 'Despite the news, we still like the stock' - StreetInsider
Acadia Scraps Prader-Willi Drug After Late-Stage Failure - BioSpace
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga
Acadia Pharmaceuticals (ACAD) Shares Dip After Trial Disappointm - GuruFocus
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):